International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationAnemia During Sequential Induction Chemotherapy and Chemoradiation for Head and Neck Cancer: The Impact of Blood Transfusion on Treatment Outcome
Introduction
Until relatively recently, surgery and radiotherapy were considered the main treatments for patients with late-stage squamous cell cancers of the head and neck (SCCHN). However, in recent years, systemic chemotherapy has increasingly been incorporated into the treatment plan. As part of primary treatment, systemic chemotherapy can be administered before (induction or neoadjuvant chemotherapy) or during (concomitant chemotherapy) radiotherapy.
The rationale underlying the use of induction chemotherapy is that drug delivery is likely to be better in untreated well-vascularized tumors, and disease may be down-staged before definitive treatment and micrometastases may be targeted (1). Studies have demonstrated that chemotherapy can reduce the rate of distant metastases and improve survival 2, 3. Induction treatment with combined cisplatin and 5-fluorouracil (5-FU) (the PF regimen) yields a 5% improvement in 5-year survival 3, 4. Recently reported Phase III studies have demonstrated that the addition of a third drug (docetaxel) to cisplatin and 5-FU (as part of the so-called TPF regimen) results in superior progression-free and overall survival rates when compared with PF 5, 6. Taken together, these data suggest that induction treatment with two- and three-drug regimens will be increasingly used in the future.
Concomitant chemotherapy during radiotherapy improves locoregional control rates and survival (4). In addition, combining chemotherapy with radiation improves the rates of organ conservation (7). The meta-analysis by Pignon et al. (2000) (4) showed that cisplatin-containing concomitant chemotherapy conferred maximum benefit in patients with SCCHN. Single-agent cisplatin is the cytotoxic agent of choice for concomitant chemoradiotherapy.
The use of chemotherapy in patients with SCCHN results in increased complication rates. The incidence and severity of radiation-induced toxicities within the radiation fields (e.g., mucositis, skin reaction, dysphagia) are increased. However, cytotoxic chemotherapy also causes systemic effects, such as myelosuppression. The incidence of Grade 3 or higher (Common Technology Criteria for Adverse Events [CTCAE] v3.0 acute toxicity criteria) neutropenia ranges from 15% to 42% in studies using cisplatin-based chemotherapy 8, 9, 10. Thrombocytopenia Grade 3 or higher is less common with reported incidences of 2%–10%. The incidence of Grade 3 or higher anemia ranges from 2% to 35%. This latter toxicity may have significant bearing on treatment outcome because it is known that low hemoglobin (Hb) concentration is associated with reduced local control after chemoradiation in patients with SCCHN 11, 12. Therefore, any move to increase use of sequential induction chemotherapy followed by concomitant chemoradiation (CCRT) is likely to be associated with a greater incidence of treatment-induced anemia and a corresponding risk of an adverse impact on treatment outcome. However, there are currently no systematic analyses of the effect of a CCRT program on Hb levels, transfusion requirements, and treatment outcomes in patients with SCCHN. In this study we therefore reviewed the incidence of anemia in a large consecutive cohort of patients treated with CCRT for locally advanced SCCHN. Furthermore, we analyzed the effect of a policy of Hb maintenance by blood transfusion on locoregional control and disease-specific survival (DSS) and overall survival (OS) rates.
Section snippets
Patient treatment protocol
Patients with SCCHN treated between 2001 and 2005 at the Royal Marsden Hospital with sequential CCRT formed the basis of this study. A retrospective review of the case notes and pharmacy records of these patients was undertaken. Two cycles of cisplatin (75 mg/m2) on Day 1 and 5-FU (1,000 mg/m2) Days 1–4 was the standard regimen used for induction chemotherapy. In patients experiencing significant (Grade 3 or higher, CTCAE v 3.0) cisplatin-induced neuro-/oto-/nephrotoxicity, carboplatin (AUC 5)
Results
One hundred and sixty-nine patients treated with definitive sequential induction CCRT were identified. The patient demographics and tumor characteristics are detailed in Table 1. The median Hb during the 12 weeks of treatment was 13.8 g/dL (range, 9.6–16.9). Data were available on Hb level before induction chemotherapy in 165 patients (median 13.1 g/dL, range, 8.8–15.8). The majority of patients (76%) had Hb measurements every week during radiotherapy.
Twenty-one patients had Hb levels <12 g/dL
Discussion
Our study showed a 39% and 81% incidence of anemia (Hb <12 g/dL) during induction chemotherapy and concomitant chemoradiotherapy, respectively. These figures are lower than those documented in two other studies of sequential CCRT. Psyrri et al.(8) reported figures of 80% and 88%, respectively, and Vokes et al.(13) reported 97% and 100%, respectively. This difference is probably accounted for by the lower dose intensity of cisplatin (75 mg/m2 every 3 weeks), the use of 4 (rather than 5) days of
References (31)
- et al.
End points for new agents in induction chemotherapy for locally advanced head and neck cancers
Ann Oncol
(2002) - et al.
Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer
Lancet
(2000) Laryngeal preservation in head and neck cancer: Multidisciplinary approach
Lancet Oncol
(2006)- et al.
Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx
Int J Radiat Oncol Biol Phys
(2001) - et al.
Influence of the hypoxic subvolume on the survival of patients with head and neck cancer
Int J Radiat Oncol Biol Phys
(1999) - et al.
Neo-adjuvant chemotherapy followed by radical chemo-radiation in treatment of advanced head and neck cancer
Eur J Cancer
(2007) - et al.
Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas
Int J Radiat Oncol Biol Phys
(2000) - et al.
Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27
Int J Radiat Oncol Biol Phys
(1998) - et al.
Prognostic factors affecting locally recurrent rectal cancer and clinical significance of hemoglobin
Int J Radiat Oncol Biol Phys
(2008) - et al.
Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: A randomised trial of the Radiation Therapy Oncology Group
Int J Radiat Oncol Biol Phys
(2007)
Anemia, tumor hypoxemia, and the cancer patient
Int J Radiat Oncol Biol Phys
A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85
Radiother Oncol
Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial
Lancet
Evaluation of the effect of routine packed red blood cell transfusion in anemic cervix cancer patients treated with radical radiotherapy
Int J Radiat Oncol Biol Phys
Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial
Lancet
Cited by (0)
This study has been accepted in abstract form for a poster discussion session at the American Society of Clinical Oncology annual conference, Chicago, IL, May 30–June 3, 2008.
C.M.N. and K.J.H. are joint senior authors.
Conflict of interest: none.